1. Rubnitz, J.E., et al., Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol, 2010. 11(6): p. 543-52.
2. Gorman, M.F., et al., Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer, 2010. 55(3): p. 421-9.
3. Ramos, N.R., et al., Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Med, 2015. 4(4): p. 665-95.
4. Roma-Rodrigues, C., et al., Targeting Tumor Microenvironment for Cancer Therapy. Int J Mol Sci, 2019. 20(4).
5. Yuan, Y., et al., Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep, 2016. 35(5): p. 2499-515.
6. Elsawa, S.F., et al., Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood, 2011. 118(20): p. 5540-9.
7. Wang, L.D. and A.J. Wagers, Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat Rev Mol Cell Biol, 2011. 12(10): p. 643-55.
8. Behrmann, L., J. Wellbrock, and W. Fiedler, Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look. Front Oncol, 2018. 8: p. 444.
9. Lane, S.W., D.T. Scadden, and D.G. Gilliland, The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood, 2009. 114(6): p. 1150-7.
10. Cogle, C.R., et al., Functional integration of acute myeloid leukemia into the vascular niche. Leukemia, 2014. 28(10): p. 1978-1987.
11. Isidori, A., et al., The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol, 2014. 7(6): p. 807-18.
12. Schmitz, J., et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005. 23(5): p. 479-90.
13. Levescot, A., et al., BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res, 2014. 74(10): p. 2669-76.
14. Gao, X., et al., Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol, 2015. 194(1): p. 438-45.
15. Xiao, P., et al., Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology, 2016. 5(1): p. e1063772.
16. Wang, Y., et al., IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival. Sci Rep, 2019. 9(1): p. 1729.
17. Hyde, R.K., et al., Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. Blood, 2010. 115(7): p. 1433-43.
18. Wang, Y., et al., IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia. Leuk Res, 2020. 96: p. 106409.
19. Alessandrino, E.P., et al., WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood, 2008. 112(3): p. 895-902.
20. Arber, D.A., et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016. 127(20): p. 2391-405.
21. Midgley, A.C., et al., 17beta-estradiol ameliorates age-associated loss of fibroblast function by attenuating IFN-gamma/STAT1-dependent miR-7 upregulation. Aging Cell, 2016. 15(3): p. 531-41.
22. Poniewierska-Baran, A., et al., Human rhabdomyosarcoma cells express functional pituitary and gonadal sex hormone receptors: Therapeutic implications. Int J Oncol, 2016. 48(5): p. 1815-24.
23. Endo, Y., et al., The interleukin-33-p38 kinase axis confers memory T helper 2 cell pathogenicity in the airway. Immunity, 2015. 42(2): p. 294-308.
24. Fehr, S., et al., Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-alpha in Whole Blood and Primary Cells from Different Species. Cell Physiol Biochem, 2015. 36(6): p. 2237-49.
25. Zwaan, C.M., et al., Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol, 2015. 33(27): p. 2949-62.
26. Lonetti, A., A. Pession, and R. Masetti, Targeted Therapies for Pediatric AML: Gaps and Perspective. Front Pediatr, 2019. 7: p. 463.
27. Han, Y., et al., Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci, 2014. 105(8): p. 933-42.
28. Stevens, A.M., et al., Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv, 2017. 1(18): p. 1387-1397.
29. Lopez-Bergami, P., E. Lau, and Z. Ronai, Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer, 2010. 10(1): p. 65-76.
30. Watson, G., Z.A. Ronai, and E. Lau, ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res, 2017. 119: p. 347-357.
31. Min, B.W., et al., Transcription of the protein kinase C-delta gene is activated by JNK through c-Jun and ATF2 in response to the anticancer agent doxorubicin. Exp Mol Med, 2008. 40(6): p. 699-708.